NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Low-Dose Aspirin and Cardiovascular Risk Reduction in Type 2 Diabetes
TL;DR
Low-dose aspirin gives Type 2 diabetes patients a significant advantage by reducing heart attack risk by 42.4% and stroke risk by 14.5% compared to non-users.
The study analyzed 10 years of health records from 11,681 adults with Type 2 diabetes, tracking aspirin use frequency and cardiovascular event outcomes across four participant groups.
This research offers hope for reducing cardiovascular deaths among Type 2 diabetes patients, potentially improving quality of life and extending healthier years for millions worldwide.
Consistent low-dose aspirin use showed the greatest cardiovascular benefits, with better outcomes observed in patients who had their diabetes well-controlled through lower HbA1c levels.
Found this article helpful?
Share it with your network and spread the knowledge!
The study found that adults with Type 2 diabetes and moderate-to-high cardiovascular risk who took low-dose aspirin were significantly less likely to experience serious cardiovascular events like heart attacks, strokes, or death compared to similar individuals who did not take aspirin.
The benefit was observed in adults with Type 2 diabetes who have moderate or high risk of cardiovascular disease, with greater benefit seen in those who took aspirin consistently and those with better-controlled blood sugar levels (lower HbA1c levels).
Adults with Type 2 diabetes who took low-dose aspirin were 42.4% less likely to have a heart attack compared to 61.2% of participants who did not take low-dose aspirin.
Type 2 diabetes is a known risk factor for cardiovascular disease, and this study specifically examines low-dose aspirin use in this high-risk population who may not have been fully represented in previous cardiovascular prevention trials.
Researchers analyzed 10 years of electronic health record data from more than 11,500 adults previously diagnosed with Type 2 diabetes who had moderate or high risk for cardiovascular events, examining aspirin use patterns and cardiovascular outcomes.
The preliminary study will be presented at the American Heart Association's Scientific Sessions 2025, taking place November 7-10 in New Orleans.
These findings are considered preliminary as they come from a research abstract presented at a scientific meeting and have not yet been peer-reviewed or published as a full manuscript in a scientific journal.
The study found that the cardiovascular benefit was greatest for individuals who took aspirin consistently throughout most of the 10-year follow-up period, showing that regular use provides stronger protection.
While low-dose aspirin use was associated with lower cardiovascular event risk regardless of blood sugar levels, the reduction was more substantial in individuals with lower HbA1c levels, indicating better-controlled diabetes.
This study specifically focuses on adults with Type 2 diabetes and moderate-to-high cardiovascular risk, a population that may not have been fully included in previous trials that showed aspirin wasn't beneficial for primary prevention in people without established cardiovascular disease.
Curated from NewMediaWire
